Kronos Bio (KRON) Revenue & Revenue Breakdown
Kronos Bio Revenue Highlights
Latest Revenue (Y)
$9.85M
Latest Revenue (Q)
$2.37M
Kronos Bio Revenue by Period
Kronos Bio Revenue by Year
Date | Revenue | Change |
---|---|---|
2024-12-31 | $9.85M | 56.62% |
2023-12-31 | $6.29M | 100.00% |
2022-12-31 | - | 100.00% |
2021-12-31 | - | 100.00% |
2020-12-31 | - | 100.00% |
2019-12-31 | - | 100.00% |
2018-12-31 | - | - |
Kronos Bio generated $9.85M in revenue during NA 2024, up 56.62% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Kronos Bio Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-09-30 | $2.37M | -11.83% |
2024-06-30 | $2.69M | 6.67% |
2024-03-31 | $2.52M | 10.24% |
2023-12-31 | $2.29M | 149.29% |
2023-09-30 | $917.00K | -50.80% |
2023-06-30 | $1.86M | 52.66% |
2023-03-31 | $1.22M | 100.00% |
2022-12-31 | - | 100.00% |
2022-09-30 | - | 100.00% |
2022-06-30 | - | 100.00% |
2022-03-31 | - | 100.00% |
2021-12-31 | - | 100.00% |
2021-09-30 | - | 100.00% |
2021-06-30 | - | 100.00% |
2021-03-31 | - | 100.00% |
2020-12-31 | - | 100.00% |
2020-09-30 | - | 100.00% |
2020-06-30 | - | 100.00% |
2020-03-31 | - | 100.00% |
2019-12-31 | - | 100.00% |
2019-09-30 | - | 100.00% |
2019-06-30 | - | 100.00% |
2019-03-31 | - | - |
Kronos Bio generated $2.37M in revenue during Q3 2024, up -11.83% compared to the previous quarter, and up 127.15% compared to the same period a year ago.
Kronos Bio Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
CTMX | CytomX Therapeutics | $138.10M | $33.43M |
GOSS | Gossamer Bio | $114.70M | $9.48M |
SPRO | Spero Therapeutics | $47.98M | $13.47M |
MRUS | Merus | $36.13M | $11.77M |
CCCC | C4 Therapeutics | $20.76M | - |
GBIO | Generation Bio | $19.89M | $4.09M |
KRON | Kronos Bio | $9.85M | $2.37M |
CYCN | Cyclerion Therapeutics | $2.00M | $194.00K |
ADXN | Addex Therapeutics | $1.61M | $235.00K |
LYRA | Lyra Therapeutics | $1.53M | $195.00K |
CRNX | Crinetics Pharmaceuticals | $1.04M | - |
INBX | Inhibrx Biosciences | $200.00K | - |
ACHL | Achilles Therapeutics | - | - |
EWTX | Edgewise Therapeutics | - | - |
REPL | Replimune Group | - | - |
NVCT | Nuvectis Pharma | - | - |
NXTC | NextCure | - | - |
ASMB | Assembly Biosciences | - | $6.84M |
ERAS | Erasca | - | - |
LYEL | Lyell Immunopharma | - | $34.00K |
LRMR | Larimar Therapeutics | - | - |